Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of *PTEN* mRNA

Mohammad Ariful Islam, Yingjie Xu, Wei Tao , Jessalyn M. Ubellacker, Michael Lim, Daniel Aum, Gha Young Lee, Kun Zhou, Harshal Zope, Mikyung Yu, Wuji Cao, James Trevor Oswald, Meshkat Dinarvand, Morteza Mahmoudi , Robert Langer, Philip W. Kantoff, Omid C. Farokhzad, Bruce R. Zetter and Jinjun Shi

Correction to: *Nature Biomedical Engineering* <https://doi.org/10.1038/s41551-018-0284-0>, published online 17 September 2018.

The authors wish to add the following sentence into the ‘Competing interests’ section of this Article: “P.W.K. has investment interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences and Tarveda Therapeutics, is a company board member for Context Therapeutics LLC, is a consultant and scientific advisory board member for BIND Biosciences, Inc., BN Immunotherapeutics, DRGT, GE Healthcare, Janssen, Metamark, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics and Thermo Fisher, and serves on data safety monitoring boards for Genentech/Roche and Merck.” This has now been included.

Published online: 23 November 2018

<https://doi.org/10.1038/s41551-018-0331-x>